Neuropsychiatric Adverse Events Following Antiretroviral Therapy in People Living with HIV: A Real-World Study of Dynamic Trends and Risk Factors in Hangzhou, China

References

• Mallewa J, Szubert AJ, Mugyenyi P, et al. Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial. Lancet HIV. 2018;5(5):e231–e240. doi:10.1016/S2352-3018(18)30038-9
   PubMed Web of Science ®Google Scholar
• Shadloo B, Amin-Esmaeili M, Motevalian A, et al. Psychiatric disorders among people living with HIV/AIDS in Iran: prevalence, severity, service utilization and unmet mental health needs. J Psychosom Res. 2018;110:24–31. doi:10.1016/j.jpsychores.2018.04.012
   PubMed Web of Science ®Google Scholar
• Dalwadi DA, Ozuna L, Harvey BH, et al. Adverse neuropsychiatric events and recreational use of efavirenz and other HIV-1 antiretroviral drugs. Pharmacol Rev. 2018;70(3):684–711. doi:10.1124/pr.117.013706
   PubMed Web of Science ®Google Scholar
• Wang N, Wang M, Xin X, et al. Exploring the relationship between anxiety, depression, and sleep disturbance among HIV patients in china from a network perspective. Front Psychiatry. 2021;12:764246. doi:10.3389/fpsyt.2021.764246
   PubMed Web of Science ®Google Scholar
• Wang T, Fu H, Kaminga AC, et al. Prevalence of depression or depressive symptoms among people living with HIV/AIDS in China: a systematic review and meta-analysis. BMC Psychiatry. 2018;18(1):160. doi:10.1186/s12888-018-1741-8
   PubMedGoogle Scholar
• Yuan Q, Li F, Ruan Y, et al. Meta-analysis of the prevalence of depression among Chinese HIV/AIDS patients. Chin J AIDS STD. 2021;27(1):45–49.
   Google Scholar
• Cai S, Liu L, Wu X, et al. Depression, anxiety, psychological symptoms and health-related quality of life in people living with HIV. Patient Prefer Adherence. 2020;14:1533–1540. doi:10.2147/PPA.S263007
   PubMed Web of Science ®Google Scholar
• Heaton RK, Franklin DR, Deutsch R, et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis. 2015;60(3):473–480. doi:10.1093/cid/ciu862
   PubMed Web of Science ®Google Scholar
• Lapadula G, Bernasconi DP, Bai F, et al. Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances. AIDS. 2020;34(1):53–61. doi:10.1097/QAD.0000000000002377
   PubMed Web of Science ®Google Scholar
• Phongsamart W, Jantarabenjakul W, Chantaratin S, et al. Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand. J Int AIDS Soc. 2022;25(1):e25862. doi:10.1002/jia2.25862
   PubMed Web of Science ®Google Scholar
• Mugusi S, Ngaimisi E, Janabi M, et al. Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin. Eur J Clin Pharmacol. 2018;74(11):1405–1415. doi:10.1007/s00228-018-2499-0
   PubMed Web of Science ®Google Scholar
• Masimirembwa C, Dandara C, Leutscher PD. Rolling out efavirenz for HIV precision medicine in Africa: are we ready for pharmacovigilance and tackling neuropsychiatric adverse effects? OMICS. 2016;20(10):575–580. doi:10.1089/omi.2016.0120
   PubMed Web of Science ®Google Scholar
• Abah IO, Akanbi M, Abah ME, et al. Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz. Germs. 2015;5(3):83–91. doi:10.11599/germs.2015.1075
   PubMedGoogle Scholar
• Law JKC, Butler LT, Hamill MM. Predictors of discontinuation of efavirenz as treatment for HIV, due to neuropsychiatric side effects, in a multi-ethnic sample in the United Kingdom. AIDS Res Hum Retroviruses. 2020;36(6):459–466. doi:10.1089/aid.2019.0193
   PubMed Web of Science ®Google Scholar
• Xu L, Peng W, Song X, et al. Correction to: pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study. BMC Infect Dis. 2021;21(1):185. doi:10.1186/s12879-021-05880-8
   PubMed Web of Science ®Google Scholar
• Fernández-Bargiela N, Rotea-Salvo S, Margusino-Framiñán L, et al. Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study. Eur J Hosp Pharm. 2022;29(4):207–211. doi:10.1136/ejhpharm-2020-002374
   PubMedGoogle Scholar
• Fahrni ML, Misran NFL, Abidin ZZ, et al. Clinical predictors of efavirenz-based regimen treatment durability: a two-year case-control study of antiretroviral-naïve patients. J Infect Public Health. 2023;16(1):96–103. doi:10.1016/j.jiph.2022.12.001
   PubMed Web of Science ®Google Scholar
• Hua W, Wang S, Wang X, et al. Neuropsychiatric adverse events during 12 months of treatment with efavirenz in treatment-naïve HIV-infected patients in china: a prospective cohort study. Front Psychiatry. 2021;12:579448. doi:10.3389/fpsyt.2021.579448
   PubMed Web of Science ®Google Scholar
• Scarsi KK, Havens JP, Podany AT, et al. HIV-1 integrase inhibitors: a comparative review of efficacy and safety. Drugs. 2020;80(16):1649–1676. doi:10.1007/s40265-020-01379-9
   PubMed Web of Science ®Google Scholar
• Chan P, Goh O, Kroon E, et al. Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort. AIDS Res Ther. 2020;17(1):1. doi:10.1186/s12981-019-0257-8
   PubMed Web of Science ®Google Scholar
• Mwebaza J, Meya D, Musiime V, et al. Prevalence of neuropsychiatric adverse events and associated factors among adult patients on dolutegravir attending Mulago ISS clinic. HIV Med. 2023;24(4):491–501. doi:10.1111/hiv.13428
   PubMed Web of Science ®Google Scholar
• Yagura H, Watanabe D, Kushida H, et al. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis. 2017;17(1):622. doi:10.1186/s12879-017-2717-x
   PubMedGoogle Scholar
• Zhong M, Li M, Qi M, et al. A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China. Front Immunol. 2023;13:1033098. doi:10.3389/fimmu.2022.1033098
   PubMed Web of Science ®Google Scholar
• Chen GJ, Lee YL, Lee CH, et al. Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV. J Antimicrob Chemother. 2020;75(10):2986–2993. doi:10.1093/jac/dkaa287
   PubMed Web of Science ®Google Scholar
• Xiao J, Liu Y, Li B, et al. Anxiety, depression, and sleep disturbances among people on long-term efavirenz-based treatment for HIV: a cross-sectional study in Beijing, China. BMC Psychiatry. 2022;22(1):710. doi:10.1186/s12888-022-04366-4
   PubMed Web of Science ®Google Scholar
• Zhou BF; Cooperative Meta-Analysis Group of the Working Group on Obesity in China. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults--study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci. 2002;15(1):83–96.
   PubMed Web of Science ®Google Scholar
• Weinberg JL, Kovarik CL. The WHO Clinical Staging System for HIV/AIDS. Virtual Mentor. 2010;12(3):202–206. doi:10.1001/virtualmentor.2010.12.3.cprl1-1003
   PubMedGoogle Scholar
• Xi S, Gu Y, Guo H, et al. Sleep quality status, anxiety, and depression status of nurses in infectious disease department. Front Psychol. 2022;13:947948. doi:10.3389/fpsyg.2022.947948
   PubMed Web of Science ®Google Scholar
• Al Maqbali M. Sleep disturbance among frontline nurses during the COVID-19 pandemic. Sleep Biol Rhythms. 2021;19(4):467–473. doi:10.1007/s41105-021-00337-6
   PubMed Web of Science ®Google Scholar
• Fabbri M, Beracci A, Martoni M, et al. Measuring subjective sleep quality: a review. Int J Environ Res Public Health. 2021;18(3):1082. doi:10.3390/ijerph18031082
   PubMed Web of Science ®Google Scholar
• Redman KN, Karstaedt AS, Scheuermaier K. Increased CD4 counts, pain and depression are correlates of lower sleep quality in treated HIV positive patients with low baseline CD4 counts. Brain Behav Immun. 2018;69:548–555. doi:10.1016/j.bbi.2018.02.002
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361–370. doi:10.1111/j.1600-0447.1983.tb09716.x
   PubMed Web of Science ®Google Scholar
• Liu X, Haagsma J, Sijbrands E, et al. Anxiety and depression in diabetes care: longitudinal associations with health-related quality of life. Sci Rep. 2020;10(1):8307. doi:10.1038/s41598-020-57647-x
   PubMed Web of Science ®Google Scholar
• Lkhagvasuren B, Hiramoto T, Tumurbaatar E, et al. The brain overwork scale: a population-based cross-sectional study on the psychometric properties of a new 10-item scale to assess mental distress in Mongolia. Healthcare. 2023;11(7):1003. doi:10.3390/healthcare11071003
   Web of Science ®Google Scholar
• Karakizlis H, Doerr JM, Becker A, et al. Neuropsychological Assessment of Cognitive Impairment in Kidney Transplantation (NAsKiT) and its related risk factors: a study protocol. J Nephrol. 2022;35(7):1933–1941. doi:10.1007/s40620-022-01376-z
   PubMed Web of Science ®Google Scholar
• Christodoulou C, Michopoulos J, Tournikioti K, et al. Hospital Anxiety and Depression Scale. A quantitative analysis in medical outpatients, psychiatric outpatients and normal subjects. Psychiatriki. 2010;21(4):279–286.
   PubMedGoogle Scholar
• Xie N, Yan H, Ding J, et al. Reliability and validity analysis of the Hospital Anxiety and Depression Scale among HIV/AIDS patients. Chin J AIDS STD. 2020;26(12):1328–1331.
   Google Scholar
• Zhang YT, Huang T, Zhou F, et al. Correlation between anxiety, depression, and sleep quality in college students. Biomed Environ Sci. 2022;35(7):648–651. doi:10.3967/bes2022.084
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18(1):56–63. doi:10.1111/hiv.12468
   PubMed Web of Science ®Google Scholar